This page shows the latest bNAb news and features for those working in and with pharma, biotech and healthcare.
Gilead is testing the drug in combination with other drugs including two broadly neutralising antibody (bNAbs) – PGT121 and GS-9721 – and other candidates such as an HIV vaccine candidate developed by
GS-9620 is already in early-stage clinical testing, and Gilead says that it now intends to start human trials of an improved bNAb candidate - PGT121 derivative GS-9722. ... of bNAbs and a TLR7 agonist, which could have the potential to achieve long-term
Company executives also highlighted GSK's anti-infectives pipeline - including long-acting integrase inhibitor cabotegravir and broadly neutralising antibodies (bnAbs) in development at its ViiV subsidiary - which are both part of
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...